Loading clinical trials...
Loading clinical trials...
The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcom...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Boehringer Ingelheim
NCT05722340 · Lung Diseases, Interstitial
NCT06572384 · Lung Diseases, Interstitial
NCT04707781 · Lung Diseases, Interstitial
NCT06122233 · Lung Diseases, Interstitial, Pulmonary Fibrosis
NCT05866198 · Lung Diseases, Interstitial
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions